Reddy

India-based Dr Reddy’s Laboratories has signed an agreement with Belgium’s UCB to acquire its select portfolio of products for Rs8bn (€118.6m).

Under the deal, Dr Reddy’s will acquire UCB’s established products in the areas of dermatology, respiratory and paediatrics, covering the territories of India, Nepal, Sri Lanka and Maldives.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Dr Reddy’s India business head and senior vice-president Alok Sonig said: "The acquired UCB portfolio shall accelerate Dr Reddy’s presence in the high growth areas of dermatology, respiratory and paediatrics with market leading brands like Atarax, Nootropil, Zyrtec, Xyzal, Xyzal M etc. We welcome UCB’s employees to our growing global team."

The deal will also include transfer of around UCB’s 350 employees to Dr Reddy’s, which are involved in operations of the India business.

According to Dr Reddy’s, the acquired business reported revenues of around Rs1.5bn (€22.2m) for 2014.

"The acquired business reported revenues of around Rs1.5bn for 2014."

UCB chief operating officer Mark McDade said: "UCB is in a strong position with a solid platform for continuous growth thanks to our core products and our promising pipeline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Finding the right company for our established brands in India was crucial, and Dr Reddy’s knowledge of the local market, combined with their ambitious plans and excellent reputation, convinced us they were the right choice to drive this business forward."

Dr Reddy’s intends to complete the deal by the end of first quarter of the financial year 2015-16.

Based in Brussels, UCB carries out operations in about 40 countries and reported revenue of €3.3bn in 2014.

Dr Reddy’s produces products for applications, including gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives.

Image: Dr Reddy’s to acquire Belgium-based UCB’s select portfolio of products in India. Photo: courtesy of Dr Reddy’s Laboratories.